Skip to content

Metacrine sets IPO terms

September 9, 2020

NASH biotech, Metacrine (MTCR) to raise $85M by offering 6.5M shares at a price range of $12 – $14.

Metacrine is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal, or GI, diseases. Most advanced program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases.

https://seekingalpha.com/news/3612642-metacrine-sets-ipo-terms

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: